GlobeNewswire·Aug 20, 2026, 7:00 AM ET

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

URGN

UroGen Pharma Ltd. signed a strategic Option and Research License Agreement with IntraGel Therapeutics Ltd. to gain access to IntraGel's proprietary SRGel biodegradable sustained-release platform.
The agreement grants UroGen research rights & exclusive options to license up to three additional oncology products combining the SRGel platform with compounds designated by UroGen.
UroGen received an exclusive option to acquire worldwide rights to TumoCure, an investigational cisplatin therapy for advanced head and neck cancer, pending the completion of IntraGel's Phase 2 clinical study.
In connection with the agreement, UroGen committed to an Investment Agreement to invest up to $7 million in IntraGel's equity securities.
Early clinical data presented at the 2026 ASCO Annual Meeting showed TumoCure was generally well-tolerated in Phase 1b patients, demonstrated low systemic cisplatin exposure, & provided early signs of anti-tumor activity in heavily pretreated patients.
SRGel is a water-free, solvent-free fatty-acids based polymer matrix designed to maintain high local drug concentrations within solid tumors while minimizing systemic exposure & potential toxicities.
TumoCure is currently being developed for patients with locally advanced, inoperable head and neck cancers ineligible for systemic chemoradiation via the FDA's 505(b)(2) regulatory pathway.
IntraGel executives stated the collaboration validates the SRGel platform & creates a pathway to accelerate development across multiple oncology indications beyond head and neck cancer.
UroGen's leadership noted the partnership expands their oncology pipeline & leverages IntraGel's localized drug delivery technology to complement their existing RTGel platform expertise.